Low-Dose Aspirin Halves Cancer Recurrence Risk in Patients with Specific Genetic Mutation
A new clinical trial reveals that a daily low dose of aspirin significantly reduces the risk of cancer recurrence following surgery for patients with colon or rectal cancer who possess a particular genetic alteration.
Nearly two million people globally are diagnosed with colorectal cancer each year, and between 20 and 40 percent of those patients develop metastases, complicating treatment and increasing mortality. Now, research led by a Swedish team at Karolinska Institutet and Karolinska University Hospital offers a promising new avenue for personalized cancer care. The findings, published in The New England Journal of Medicine, demonstrate a substantial benefit from a readily available and inexpensive medication.
Previous research hinted at aspirin’s potential to lower cancer risk and prevent recurrence, particularly in patients with colorectal cancer harboring mutations within the PIK3 signaling pathway. This pathway regulates crucial cellular functions like growth and division. When these genes are mutated, uncontrolled cell proliferation can occur, driving cancer development. However, earlier studies yielded inconsistent results, lacking the definitive confirmation of a randomized clinical trial.
To address this gap, researchers initiated the ALASCCA trial, a comprehensive study involving over 3,500 patients with colon and rectal cancer from hospitals across Sweden, Norway, Denmark, and Finland. Patients whose tumors exhibited a specific genetic mutation in the PIK3 signaling pathway – present in approximately 40 percent of the study population – were randomly assigned to receive either 160 mg of aspirin daily or a placebo for three years post-surgery.
The results were striking. For patients with the PIK3 mutation, aspirin reduced the risk of cancer recurrence by 55 percent compared to the placebo group. This suggests a powerful link between the genetic alteration and the drug’s effectiveness.
“Aspirin is being tested here in a completely new context as a precision medicine treatment,” explained a lead researcher. “This is a clear example of how we can use genetic information to personalize treatment and at the same time save both resources and suffering.”
Researchers believe aspirin’s protective effect stems from multiple mechanisms. It reduces inflammation, inhibits platelet function, and directly hinders tumor growth, creating a less hospitable environment for cancer cells to thrive. While the precise molecular interactions are still being investigated, the findings strongly support a biological rationale for the treatment’s success, particularly within genetically defined patient subgroups.
The implications of this study are potentially global, with the potential to reshape treatment guidelines for colon and rectal cancer. A significant advantage of aspirin, researchers emphasize, is its widespread availability and low cost compared to many modern cancer therapies.
“Aspirin is a drug that is readily available globally and extremely inexpensive compared to many modern cancer drugs, which is very positive,” a senior researcher stated.
The study was funded by the Swedish Research Council and the Swedish Cancer Society, with researchers reporting no conflicts of interest.
Understanding Aspirin
Aspirin contains acetylsalicylic acid, a compound known for its pain-relieving, fever-reducing, and anti-inflammatory properties. Classified as a non-steroidal anti-inflammatory drug (NSAID), it typically begins to work within 30 minutes. In lower doses, it’s also used to prevent blood clots.
However, aspirin is not without potential side effects. Common issues include stomach problems and an increased risk of bleeding. Individuals with stomach ulcers, bleeding disorders, or asthma should avoid its use. While available over-the-counter in higher doses, caution is advised, especially when combined with other blood-thinning medications or alcohol.
The researchers are optimistic that these findings will pave the way for more targeted and effective cancer treatments, offering hope to millions affected by this devastating disease.
Keep reading
- Latest Advances in Alzheimer’s Disease Treatment and Diagnosis (news-usa.today)
